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Abstract
Background: Emerging evidence demonstrates that microRNAs (miRNAs) play an important role in regulation of
cell growth, invasion and metastasis through inhibiting the expression of their targets. It has been reported that
miR-130a-3p controls cell growth, migration and invasion in a variety of cancer cells. However, it is unclear whether
miR-130a-3p regulates epithelial-mesenchymal transition (EMT) in drug resistant cancer cells. Therefore, in the
current study, we explore the role and molecular mechanisms of miR-130a-3p in gemcitabine resistant (GR)
hepatocellular carcinoma (HCC) cells.
Methods: The real-time RT-PCR was used to measure the miR-130a-3p expression in GR HCC cells compared with
their parental cells. The wound healing assay was conducted to determine the cell migratory activity in GR HCC
cells treated with miR-130a-3p mimics. The migration and invasion assays were also performed to explore the role
of miR-130a-3p in GR HCC cells. Western blotting analysis was used to measure the expression of Smad4, E-
cadherin, Vimentin, and MMP-2 in GR HCC cells after depletion of Smad4. The luciferase assay was conducted to
validate whether Smad4 is a target of miR-130a-3p. The student t-test was used to analyze our data.
Results: We found the down-regulation of miR-130a-3p in GR HCC cells. Moreover, we validate the Smad4 as a
potential target of miR-130a-3p. Furthermore, overexpression of miR-130a-3p suppressed Smad4 expression,
whereas inhibition of miR-130a-3p increased Smad4 expression. Consistently, overexpression of miR-130a-3p or
down-regulation of Smad4 suppressed the cell detachment, attachment, migration, and invasion in GR HCC cells.
Conclusions: Our findings provide a molecular insight on understanding drug resistance in HCC cells. Therefore,
activation of miR-130a-3p or inactivation of Smad4 could be a novel approach for the treatment of HCC.
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Background
Liver cancer is one of the most frequently diagnosed can-
cers in the United States [1]. An estimated 35,660 new
cases and 24,550 cancer deaths will be occurred from liver
cancer in 2015 in the US [1]. It has been reported that
782,500 new liver cancer cases and 745,500 deaths
occurred worldwide during 2012, and half of the total
number of cases and deaths are from China [2]. Most
primary liver cancers are hepatocellular carcinoma (HCC).
The some factors have been reported to contribute to
HCC, such as aflatoxin, chronic hepatitis B virus infection,
obesity, type 2 diabetes, heavy alcohol consumption, and
smoking [3, 4]. The treatments for HCC include surgi-
cal resection, liver transplantation and ablation, and
chemotherapy. Since most HCC patients are diagnosed
at the advanced stages, systemic chemotherapy is
required. However, HCC patients often acquire drug
resistance to chemotherapy, leading to limited survival
benefits, suggesting that understanding and overcom-
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functions through binding to the 3′ untranslated region
(3′UTR) of target mRNA, leading to the degradation of
the mRNA or translational inhibition of functional pro-
teins. Emerging evidence has demonstrated that miR-
NAs are critically involved in the development and
progression of human cancers including HCC [5–7]. For
example, miR-93 promotes cell proliferation via target-
ing PTEN in osteosarcoma cells [5]. One study showed
that miR-106b promotes colorectal cancer cell migration
and invasion through directly targeting DLC1 [6]. Re-
cently, a growing body of data implicates that micorR-
NAs (miRNAs) play an essential role in drug resistance
through inhibition of its downstream targets in human
cancers [8, 9]. For example, upregulated miR-182 in-
creases drug resistance in cisplatin-treated HCC cells
through regulation of TP53INP1 [10]. Furthermore,
miR-340 reversed cisplatin resistance of HCC cell lines
via regulating Nrf2-dependent antioxidant pathway [11].
Liu et al. found that miR-222 regulates sorafenib resist-
ance and enhances tumorigenicity in HCC through gov-
erning PI3K/Akt pathway [12]. Another study revealed
that restoration of miR-193b sensitizes HBV-associated
HCC cells to sorafenib [13]. Moreover, reprogramming
using miR-302 improves drug sensitivity in HCC cells
through down-regulation of AOF2, which caused H3K4
methylation and c-Myc repression [14]. Yang et al.
found that miR-223 modulated multidrug resistance by
downregulation of ABCB1 in HCC cells [15]. Emerging
evidence has also suggested that miR-338-3p [16], let-7b
[17], miR-942 [18], miR-612 [19], miR-21 [20], miR-26b
[21], miR-34a [22], miR-216a/217 [23], miR-193a-3p
[24, 25], and miR-122 [26, 27] are critically involved
in drug resistance in HCC cells. These reports define
that targeting miRNAs could be a promising approach
to overcome drug resistance.
Early studies reported that miR-130a was directly in-
volved in the development of chemoresistance [28–30].
Down-regulation of miR-130a was found in a panel of
paclitaxel- and cisplatin-resistant ovarian cancer cells
[28, 31], gefitinib-resistant non-small cell lung cancer
(NSCLC) cells [32], and paclitaxel-resistant prostate
cancer cells [33]. Consistently, docetaxel-resistant head
and neck squamous cell carcinoma cell lines have lower
expression of miR-130a-3p compared with their parental
cells [29]. Moreover, it has been reported that miR-130a
targets MET and induces TRAIL-sensitivity in NSCLC
cells [30]. Furthermore, one study showed that miR-130a
was down-regulated in triple-negative breast cancer,
which is associated with chemoresistance [34]. Interest-
ingly, miR-130a was found to be upregulated in
cisplatin-resistant ovarian cancer cells [35, 36]. Although
these studies indicated miR-130a as a key role in che-
moresistance in human cancer cells, the molecularmechanism of miR-130a-meidated drug resistance has not
been fully elucidated. Therefore, the goal of this study was
to explore the role of miR-130a-3p in gemcitabine resist-
ant (GR) hepatocellular carcinoma (HCC) cells. We found
the down-regulation of miR-130a-3p in GR HCC cells.
More importantly, Smad4 was validated as a potential
target of miR-130a-3p. Notably, overexpression of miR-
130a-3p suppressed the cell migration, and invasion in GR
HCC cells partly through down-regulation of Smad4. Our
findings suggest that activation of miR-130a-3p or inacti-
vation of Smad4 could be a novel approach for the treat-
ment of HCC.
Methods
Cell culture, reagents and antibodies
HepG2, HepG2 GR, SMMC-7721, SMMC-7721 GR cells
were cultured at 37 °C in 5 % CO2 in Dulbecco’s modi-
fied Eagle’s medium (DMEM; Gibco, Gaithersburg, MD,
USA) supplemented with 10 % fetal bovine serum. The
secondary antibodies and primary antibodies against
Smad4, MMP2 and GAPDH were bought from Santa
Cruz Biotechnology (Santa Cruz, CA). Anti-Vimentin,
anti-E-cadherin antibodies were obtained from Abcam.
Wound healing assay
The HCC cells and HCC GR cells were seeded in 6-well
plate until the cells grew to 90–95 % confluency. The
scratch wound was generated in the surface of the plates
using a pipette tip in cells with miR-130a-3p mimic
transfection or Smad4 siRNA treatment. Photographic
images were taken from HCC and HCC GR cells at 0
and 20 h.
Cell attachment and detachment assay
Cell attachment and detachment assays were con-
ducted as described before [37–39]. Briefly, for at-
tachment assay, HCC GR cells transfected with
Smad4 siRNA or miR-130a-3p mimics were seeded in
24-well plates at 5 × 104 cells per well. Unattached
cells were removed after 1 h incubation, and the at-
tached cells were counted after trypsinization. The
data were presented as a percentage of the attached
cells compared to total cells. For cell detachment
assay, after 24 h incubation, the cells were incubated
with 0.05 % trypsin for 3 min to detach the cells.
Then, the culture medium was added to inactivate
the trypsin and the detached cells were collected. The
remaining cells were incubated with 0.25 % trypsin to
detach and counted. The data were presented as a
percentage of the detached cells to total cells.
Transwell migration and invasion assays
The migration of HCC cells was conducted using a 24-well
Transwell chamber (Corning) with gelatin-coated
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HCC cells was performed using Transwell inserts with
Matrigel (BD Biosciences). After incubation for 20 h, the
upper surfaces of the Transwell chambers were scraped
with cotton swabs, and the migrated and invaded cells were
fixed with 4 % paraformaldehyde, and then stained with
Giemsa solution. The stained cells were photographed and
counted under a light microscope in five randomly-selected
fields.
RNA extraction and reverse transcription-PCR analysis for
gene expression
The total RNA from HCC cells and HCC GR cells was
isolated with Trizol (Invitrogen) and purified with
RNeasy Mini Kit and RNase-free DNase Set (Qiagen) ac-
cording to the manufacturer’s protocols. The primer se-
quences for target genes were as follows: Smad4
(forward, 5′-CGG ACA TTA CTG GCC TGT TC-3′;
reverse, 5′-TAG GGC AGC TTG AAG GAA ACC-3′;
E-cadherin (forward, 5′-GAA GTG TCC GAG GAC
TTT GG -3′; reverse, 5′-CAG TGT CTC TCC AAA
TCC GAT A -3′); MMP-2 (forward, 5′-TAT GGC TTC
TGC CCT GAG AC -3′; reverse, 5′-CAC ACC ACA
TCT TTC CGT CA -3′); Vimentin (forward, 5′-TGT
CCA AAT CGA TGT GGA TGT TTC-3′; reverse, 5′-
TTG TAC CAT TCT TCT GCC TCC TG-3′); GAPDH
(forward, 5′-CAG CCT CAA GAT CAT CAG CA -3′; re-
verse, 5′-TGT GGT CAT GAG TCC TTC CA-3′). The ex-
pression of GAPDH was used as internal control. RT-PCR
amplifications were performed as described before [40].
Protein extraction and Western blotting
Cells were harvested and lysed with RIPA buffer (1 × PBS,
1 % Nonidet P40, 0.5 % sodium deoxycholate, 0.1 % SDS,
and protease inhibitor cocktail). The protein concentra-
tions were measured using the Bio-Rad protein assay
kit (Bio-Rad Laboratories, CA). Immunoblotting was
conducted with standard protocols as described previ-
ously [41].
miRNA real-time RT-PCR
The miRNA real-time RT-PCR assay was performed using
miR-130a-3p TaqMan MicroRNA Assay Kit (Applied
Biosystems). Briefly, ten nanogram of total RNA was re-
verse transcribed into cDNA and then real-time PCR was
performed using specific primers for miR-130a-3p as de-
scribed previously [37]. U6 was used as an endogenous
control for normalization.
Transfection
Cells were seeded in six-well plates and transfected with
different Smad4 siRNAs (Genepharma, Shanghai,
China), miR-130a-3p mimics and miR-130a-3p inhibitors
(Genepharma, Shanghai, China) using Lipofectamine2000 as described earlier [40]. After the indicated pe-
riods of incubation, the cells were subjected to further
analysis as presented under the results section.Luciferase assays
The wild-type and mutant Smad4 3′-UTR were ampli-
fied by PCR and cloned in pMIR-REPORT (Ambion)
with firefly luciferase. A total of 5 × 104 cells treated
with control, miR-130a-3p mimics, or miR-130a-3p in-
hibitors were transfected with wild-type or mutants of
Smad4 3′ UTR luciferase reporters together with Renilla
plasmid. After 48 h of transfection, the firefly and
Renilla luciferase were measured according to the
manufacturer’s protocols (Promega). The firefly lucif-
erase activities were normalized to Renilla luciferase
activities.Statistical analysis
All experiments were repeated at least 3 times. Values
were shown as means ± SEM and analyzed using
GraphPad Prism 4.0 (Graph pad Software, La Jolla,
CA). Statistical comparisons between different groups
were performed using Student t test. P < 0.05 was con-
sidered statistically significant.Results
Down-regulation of miR-130a-3p in HCC GR cells
First, the miRNA array in both HepG2 GR and HepG2
cells was performed. We found that multiple miRNAs
were down-regulated and some miRNAs were up-regulate
in HepG2 GR cells (data not shown). This finding
indicates that further investigations are required to ex-
plore the mechanisms of GR-mediated miRNA dysregula-
tion. Notably, miR-130a-3p expression was significantly
down-regulated in HepG2 GR cells. It has been reported
that miR-130a was critically involved in drug resistance
[32, 33]. Therefore, we validated whether miR-130a-3p
has changes in HCC GR cells compared with their paren-
tal cells. Our real-time RT-PCR results showed that miR-
130a-3p was down-regulated in both HepG2 GR and
SMMC-7721 GR cells (Fig. 1a). Recently, miR-130a was
found to inhibit cell migration and invasion in human
breast cancer cells [42]. In line with this finding, our
wound-healing assay showed that miR-130a-3p mimics
significantly decreased numbers of cells migrating across
the wound in HepG2 GR and SMMC 7721 GR cells
(Fig. 1b). Moreover, our invasion assay results revealed
that miR-130a-3p mimics suppressed cell invasion in
HCC GR cells compared with control miRNA treatment
(Fig. 1c). Additionally, we observed that miR-130a-3p
mimics inhibited the cell detachment and attachment in
both HCC GR cells (Fig. 1d).
Fig. 1 (See legend on next page.)
Liu et al. Journal of Experimental & Clinical Cancer Research  (2016) 35:19 Page 4 of 11
(See figure on previous page.)
Fig. 1 Down-regulation of miR-130a-3p in HCC GR cells. a Real-time RT-PCR assay was performed to detect the levels of miR-130a-3p in HCC and
HCC GR cells. *p < 0.05, vs HCC cells. b Wound assays were performed to compare the migratory potential of HepG2 GR and SMMC-7721 GR cells
after miR-130a-3p mimics treatment. c Top panel: Invasion assay was conducted to measure the invasive capacity in HepG2 GR and SMMC-7721 GR
cells after miR-130a-3p mimics treatment. Bottom panel: Quantitative results are illustrated for top panel. *P < 0.05, vs control. d Cell attachment and
detachment assays were conducted in HepG2 GR and SMMC-7721 GR cells after miR-130a-3p mimics treatment. *P < 0.05, vs control
Fig. 2 Smad4 is associated with miR-130a-3p expression. a Top panel: Real-time RT-PCR assay was performed to detect the mRNA level of Smad4 in HCC
GR cells treated with miR-130a-3p mimics. miR-130a-3p was measured by miRNA real-time RT-PCR in HCC GR cells after miR-130a-3p mimic transfection.
Bottom panel: Real-time RT-PCR assay was performed to detect the mRNA level of Smad4 in HCC cells treated with miR-130a-3p inhibitor. miR-130a-3p
was measured by miRNA real-time RT-PCR in HCC cells after miR-130a-3p inhibitor treatment. *p< 0.05, vs control. b Left panel: Western blotting analysis
was conducted to measure the expression of Smad4 in HCC cells treated with miR-130a-3p inhibitor and in HCC GR cells treated with miR-130a-3p mimic.
Right panel: Quantitative results are illustrated for left panel
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expression
To further determine the mechanism of miR-130a-3p-
regulated invasion in HCC GR cells, we sought to iden-
tify the target of miR-130a-3p. According to the data
from TargetScan, PicTar, and miRanda, Smad4 could be
a potential target of miR-130a. Although it has been re-
ported that miR-130a targeted Smad4 in granulocytic
cells [43], another study did not support this report in
human cancer cells [44]. Therefore, further investigation
is required for validation of Smad4 as a miR-130a target.
Our results from RT-PCR demonstrated that miR-130a-
3p mimic treatment led to decreased Smad4 in HCC GR
cells, whereas miR-130a-3p inhibitor treatment caused the
up-regulation of Smad4 in HCC cells (Fig. 2a). Western
blotting analysis further demonstrated that up-regulation
of Smad4 was observed in HCC cells after miR-130a-3p
inhibitor treatment (Fig. 2b). Consistently, the down-
regulation of Smad4 was showed in HCC GR cells treated
with miR-130a-3p mimic (Fig. 2b). In addition, we found
high expression of Smad4 in HCC GR cells, which have
lower expression of miR-130a-3p (Fig. 3a), suggesting that
Smad4 could be a target of miR-130a-3p.
Smad4 is a downstream target of miR-130a-3p
Bioinformatics analysis indicated that the Smad4 3′UTR
harbors potential miR-130a-3p target sites (Fig. 3b). To
further verify the Smad4 as a potential target of miR-
130a-3p, we conducted the reporter assay in HCC cells
with the luciferase gene driven by either wild-type or
mutated Smad4 3′UTR sequences. We found that it hasFig. 3 Smad4 is a downstream target of miR-130a-3p. a Left panel: Real-tim
GR cells. *p < 0.05 vs control. Right panel: Western blotting analysis was pe
panel: Sequences of target sites for miR-130a-3p in Smad4 are shown. Right p
of miR-130a-3p to Smad4 3′-UTR. WT: wild type; Mut: mutation. *p < 0.05 vs coa significant reduction in luciferase activity with wild-
type Smad4, but not mutant Smad4, in HepG2 GR cells
transfected with miR-130a-3p mimic (Fig. 3b). Consist-
ently, miR-130a-3p inhibitors treatment led to increased
luciferase activity with wild-type Smad4 in HepG2 cells
(Fig. 3b). Taken together, these findings further validate
that Smad4 is a downstream target of miR-130a-3p.
Down-regulation of Smad4 reverses EMT to MET in HCC
GR cells
Our previous study has shown that HCC GR cells have
EMT phenotype [40]. To determine whether Smad4
plays a key role in GR-mediated EMT, we depleted the
Smad4 using its specific siRNAs in HepG2 GR and
SMMC 7721 GR cells. We found significant down-
regulation of Smad4 by its siRNAs using RT-PCR and
Western blotting analysis, respectively (Fig. 4a). Next,
we used Smad4 siRNA1 to conduct the following experi-
ments. We observed that both HepG2 GR and SMMC
7721 GR cells with Smad4 siRNA transfection displayed
round cell-like morphology (Fig. 4b), suggesting that de-
pletion of Smad4 reversed EMT to MET (mesenchymal
to epithelial transition) in HCC GR cells.
Depletion of Smad4 regulated EMT markers in HCC GR
cells
To further confirm the reversal of EMT by knockdown
of Smad4 in HCC GR cells, we detected the expression
of EMT molecular markers. Our RT-PCR results showed
that depletion of Smad4 decreased E-cadherin mRNA,
but increased Vimentin and MMP2 mRNA levels ine RT-PCR assay was used to detect the mRNA level of Smad4 in HCC
rformed to measure the expression of Smad4 in HCC GR cells. b Left
anel: Luciferase reporter assays were performed to identify the binding
ntrol
Fig. 4 Down-regulation of Smad4 reverses EMT to MET in HCC GR cells. a Left panel: Real-time RT-PCR assay was used to detect the mRNA level
of Smad4 in HepG2 GR cells transfected with Smad4 siRNAs. Right panel: Western blotting analysis was performed to measure the expression of
Smad4 in HepG2 GR cells after Smad4 siRNA transfection. b Down-regulation of Smad4 caused reversal of EMT phenotype of HCC GR cells. HepG2
GR and SMMC-7721 GR cells transfected with control siRNA exhibited a fibroblastic-type phenotype, while these GR cells transfected with Smad4 siRNA
display round-like epithelial cell shape. c HCC GR cells transfected with control siRNA or Smad4 siRNA were used for assessing the expression of EMT
markers using Real-time RT-PCR. * P< 0.05, ** P< 0.01 vs control. d HCC GR cells transfected with control siRNA or Smad4 siRNA were used for assessing
the expression of EMT markers by Western blotting analysis. CS: control siRNA; SS: Smad4 siRNA
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ently, the results from our Western blotting validated
that E-cadherin was increased, while Vimentin and
MMP2 are down-regulated after depletion of Smad4 in
HepG2 GR and SMMC 7721 GR cells (Fig. 4d). These
results suggest that down-regulation of Smad4 caused
the reversal of EMT to MET phenotype.Down-regulation of Smad4 inhibited cell migration and
invasion in HCC GR cells
To explore whether Smad4 is involved in regulation of
cell motility, we performed the migration and invasion
assays in HCC GR cells after Smad4 siRNA transfection.
We found that Smad4 siRNA transfecton led to inhib-
ition of cell migration and invasion in both HepG2 GR
Fig. 5 Down-regulation of Smad4 inhibited cell migration and invasion in HCC GR cells. a Top panel: Transfection of HepG2 GR cells and SMMC-7721
GR cells with Smad4 siRNA inhibited cell migration. Bottom panel: Smad4 siRNA suppressed cell invasion of HepG2 GR and SMMC-7721 GR cells by
Transwell invasion assay. b Quantitative results are illustrated for panel a. c SMMC-7721 GR cells transfected with Smad4 siRNA caused decreased motility
capacity as assessed by Wound healing assay. d HepG2 GR and SMMC-7721 GR cells transfected with Smad4 siRNA inhibited the attachment and
detachment of cells. * P< 0.05 vs control siRNA
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healing assay further demonstrated that depletion of
Smad4 suppressed cell motility in both HCC GR cells
(Fig. 5c). In support of this, Smad4 siRNA treatment
inhibited cell detachment and attachment in HepG2 GR
and SMMC 7721 GR cells (Fig. 5d). Altogether, Smad4
plays a pivotal role in cell migration and invasion in
HCC cells.Over-expression of miR-130a-3p enhances GR cells to
gemcitabine sensitivity
To investigate whether reintroduction of miR-130a-3p
enhances GR cells to gemcitabine sensitivity, we per-
formed MTT assay in miR-130a-3p mimics transfected
GR cells. We found that reintroduction of miR-130a-3p
in HepG2 GR cells significantly attenuated cell growth
inhibition from 60 to 80 % induced by 65 μg/ml gemci-
tabine (Fig. 6). Similar result was observed in SMMC
GR cells (Fig. 6). These results suggested that miR-130a-
3p mimics-transfected GR cells were significantly more
sensitive to gemcitabine-induced cell growth inhibition.Discussion
Recent studies have highlighted the important role of
miR-130a in HCC progression and metastasis [45–47].
One study showed that miR-130a regulated the HBV-
associated estrogen receptor alpha in human HCC cells
[48]. miR-130a expression is correlated with pathological
tumor grade in HCC [49]. Li et al. found that miR-130a
expression was significantly down-regulated in HCC
[45]. Moreover, lower expression of miR-130a was asso-
ciated with overall survival of patients with HCC [45],
suggesting that miR-130a could serve as a potential
prognostic biomarker for HCC patients. Remarkably, it
has been discovered that upregulated miR-130a in-
creased drug resistance by targeting RUNX3 and Wnt
signaling in cisplatin-treated HCC cells [47]. Our current
study revealed that miR-130a-3p was down-regulated inFig. 6 Over-expression of miR-130a-3p enhances GR cells to gemcitabine sen
mimics. *, P < 0.05 compared with control and miRNA-NCHCC GR cells and overexpression of miR-130a-3p inhib-
ited cell migration and invasion.
The data presented here demonstrated that miR-130a-
3p-regulated EMT and cell invasion through inhibition
of Smad4 in HCC GR cells. Recent studies have identi-
fied critical roles of Smad4 in tumorigenesis and EMT
processes [50, 51]. Some studies have demonstrated that
Smad4 plays tumor suppressive functions in most types
of human cancers [52, 53]. However, multiple studies
have indicated that Smad4 has oncogenic functions in sev-
eral kinds of human cancers [54]. It is clear that Smad4
exerts a tumor-promoting role in HCC. Specifically,
knockdown of Smad4 significantly reduced the colony for-
mation and migratory capacity of HCC cells [54]. More-
over, overexpression of Smad4 was observed in HCC
patient tumors compared with adjacent tissues [54].
Furthermore, knockdown of Smad4 significantly increased
E-cadherin expression in prostate cancer cells [50]. Qiao
et al. reported that miR-34a inhibited EMT in human
cholangiocarcinoma by targeting Smad4 via TGF-beta/
Smad signaling pathway [51]. In line with these findings,
our results showed that knockdown of Smad4 inhibits cell
migration, and invasion in HCC GR cells. Altogether, in-
activation of Smad4 could be a novel strategy for the treat-
ment of HCC.
A number of observations demonstrated that some
small molecules and natural compounds could regulate
the expression of miRNAs [55–57]. Multimodal syn-
thetic small molecules have been developed to target the
production of oncognic miRNAs [56]. Arsenic trioxide
has been discovered to down-regulate miR-125b expres-
sion in huma glioma [57]. More importantly, natural
compound curcumin has been reported to modulate
miR-203-mediated regulation of the Src-Akt axis in
bladder cancer [55]. Similarly, genistein inhibited cell
growth and invasion via regulation of miR-27a and miR-
34a in pancreatic cancer cells [58, 59]. Therefore, it is
required to develop small molecules and discover com-
pounds to control the expression of miRNAs in the nearsitivity. MTT assay was performed in GR cells treated with miR-130a-3p
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miR-130a-3p was decreased in HCC GR cells. Moreover,
we validated that miR-130a-3p targeted Smad4 expres-
sion. Notably, we confirmed that Smad4 plays a critical
role in regulation of migration and invasion and EMT
in HCC GR cells. Strikingly, reintroduction of miR-
130a-3p enhances GR cells to gemcitabine sensitivity.
However, transfection of mutant Smad4 without a miR-
130a-3p binding site in HepG2 cells led to gemcitabine
resistance (data not shown), suggesting that Smad4
plays a critical role in miR-130a-3p-mediated gemcita-
bine sensitivity. Altogether, our findings provide an insight
into the molecular basis involved in gemcitabine resistance.
However, further exploration is necessary to fully under-
stand the molecular insights on miR-130a-mediated drug
resistance and EMT in HCC cells.
Conclusion
In summary, our study describes a potential mechanism
for dysregulation of Smad4 by miR-130a-3p in HCC.
Taken together, upregulation of miR-130a-3p and inacti-
vation of Smad4 could be a promising approach for
achieving better treatment of HCC.
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